Acceleron Appoints Kevin F. McLaughlin as Senior Vice President and Chief Financial Officer

Acceleron Appoints Kevin F. McLaughlin as Senior Vice President and Chief Financial Officer


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 29, 2010 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced that Kevin F. McLaughlin has joined Acceleron as Senior Vice President and Chief Financial Officer.

"Kevin is a talented CFO who brings to Acceleron substantial financial and operations experience at both private and public biotechnology companies," said John Knopf, Ph.D., Chief Executive Officer of Acceleron. "As our pipeline rapidly advances and expands, we look forward to Kevin's contributions to our senior management team."

Mr. McLaughlin has more than 30 years of financial and operating management experience spanning the biotech, high tech and education industries. He most recently served as Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company. From 1996 through 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc. He joined the company as their first Chief Financial Officer where he had responsibility for private financings, partnership financings, the company's initial public offering and subsequent secondary stock offerings. Later, Mr. McLaughlin became COO, and then President and CEO, as well as serving as a member of the Board of Directors. In this capacity he was responsible for negotiating the sale of the company to GlaxoSmithKline. He began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin received a B.S. from Northeastern University and M.B.A. from Babson College.

About Acceleron Pharma

Acceleron is a privately-held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of red blood cells, bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron's scientific approach takes advantage of its unique insight into the regenerative powers of the TGF-β superfamily of proteins. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company's internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron include Advanced Technology Ventures, Alkermes, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For further information on Acceleron Pharma, please visit www.acceleronpharma.com.

 

 

 

Contact: Acceleron Pharma:
Steven Ertel, 617-649-9234
Vice President, Corporate Development
or
Media:
Suda Communications LLC
Paul Kidwell, 617-296-3854

 

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.